B Cells from Patients with Systemic Lupus Erythematosus Display Abnormal Antigen Receptor–mediated Early Signal Transduction Events

Stamatis-Nick C. Lioussis,* Birgit Kovacs,* Greg Dennis,† Gary M. Kammer,§ and George C. Tsokos‡

‡Department of Clinical Physiology, Walter Reed Army Institute of Research, Washington, DC 20307-5100; †Departments of Clinical Investigation and Medicine, Walter Reed Army Medical Center, Washington, DC 20307-5001; and §Department of Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157-1058

Abstract

To understand the molecular mechanisms that are responsible for the B cell overactivity that is observed in patients with SLE, we have conducted experiments in which the surface immunoglobulin (sIg)-mediated early cell signaling events were studied. The anti–sIgM-mediated free intracytoplasmic calcium ([Ca\(^{2+}\)]\(_i\)) responses were significantly higher in SLE B cells compared with responses of normal individuals and to those of patients with other systemic autoimmune rheumatic diseases. The anti-IgD mAb induced [Ca\(^{2+}\)]\(_i\) responses were also higher in lupus B cells than in controls. The magnitude of anti–sIgM-mediated Ca\(^{2+}\) release from intracellular stores was also increased in B cells from SLE patients compared with normal controls. The amount of inositol phosphate metabolites produced upon crosslinking of sIgM was slightly higher in patients with lupus than in normal controls, although the difference was not statistically significant. In contrast, the degree of anti–sIgM-induced protein tyrosine phosphorylation was obviously increased in lupus patients. Our study demonstrates clearly for the first time that SLE B cells exhibit aberrant early signal transduction events, including augmented calcium responses after crosslinking of the B cell receptor and increased antigen–receptor-mediated phosphorylation of protein tyrosine residues. Because the above abnormalities did not correlate with disease activity or treatment status, we propose that they may have pathogenic significance. (J. Clin. Invest. 1996. 98:2549–2557.) Key words: lymphocyte signaling • calcium responses • tyrosine phosphorylation • inositol phosphate metabolites • human autoimmunity

Introduction

SLE is considered to be the archetypal human autoimmune disease, and it is characterized by a variety of abnormalities of the immune system (1, 2). Both in human (3) and in murine models of the disease (4), B cell overactivity is considered to be responsible for the hypergammaglobulinemia and the production of a large variety of autoantibodies, some of which are convincingly involved in the pathogenesis of certain types of immune complex–mediated histological damage (5, 6). Different factors contribute to lupus B cell overactivity. Among these are defective suppressor inducer T cell subset (7), excessive help provided by certain T cell subsets (8, 9), defective Fcγ receptor-mediated suppression (10), and overreactivity to cytokines delivered to B cells in an endocrine, paracrine, or autocrine fashion (11, 12).

B cell function itself has so far been considered to be intact, but the conclusion that B lymphocytes are not intrinsically defective has been inferred indirectly (13–15). Recent evidence produced from the study of murine models suggests that B cells may be intrinsically defective (16–20). To further investigate possible inherent lupus B cell abnormalities, we examined a central aspect of their function, namely the early events of the B cell receptor (BCR)-mediated signal transduction.

Stimulation of B cells with antigens (Ags) or mAbs results in a well-regulated cascade of intracellular events, which lead to cell activation and proliferation. The ligation of the BCR complex initially causes the activation of protein tyrosine kinases (PTK) (21, 22) which, in turn, induces among other events the phosphorylation and activation of phospholipase C (PLC) isozymes PLC\(_{\gamma1}\) and PLC\(_{\gamma2}\). The latter PLC isozyme predominates in B cells (23). Activated PLC acts on membrane phosphatidylinositol 4,5-biphosphate (PIP\(_2\)) that leads to the production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (InsP\(_3\)) (24–26). DAG activates protein kinase C (PKC) (27), whereas InsP\(_3\) binds to its receptor on the endoplasmic reticulum and causes the release of free Ca\(^{2+}\) from intracellular stores (28). The increase of free intracytoplasmic Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_i\)) and activated PKC act on a variety of genes, resulting in their transcription, cellular activation, and proliferation (29, 30). Ca\(^{2+}\) is an important intracellular messenger which plays a role in a spectrum of cellular events that range from egg fertilization to apoptosis, via the regulation of signal transduction (31–35).

The BCR-complex–mediated early signal transduction events in lupus have not been investigated so far. In this communication, we present studies in which we examined the BCR-initiated Ca\(^{2+}\) responses, tyrosine phosphorylation and Ins\(_3\) production in fresh, unmanipulated B cells from SLE patients, disease and normal controls. Our results show that only

1. Abbreviations used in this paper: BCR, B cell receptor; [Ca\(^{2+}\)]\(_i\), free intracytoplasmic concentration of Ca\(^{2+}\); HRPO, horseradish peroxidase; InsP\(_i\), inositol phosphate-1; InsP\(_2\), Ins phosphate-2; InsP\(_3\), Ins 1,4,5-trisphosphate; InsP,R, InsP, receptor; ITAM, Ig(superfamily) tyrosine-based activation motif; PKA, protein kinase A; PKC, protein kinase C; PTK, protein tyrosine kinase; sIg, surface Ig.
lupus B cells display aberrant BCR-induced early cell signaling events, which may contribute to the abnormal function of SLE B cells.

Methods

Patients and controls. 21 SLE patients (18 women, 3 men) were studied. All subjects fulfilled at least 4 of the 11 revised criteria of the American Rheumatism Association for the Classification of SLE (36). The age of the patients ranged from 20 to 76 yr (mean±SD = 44±14.2). Patients who were receiving glucocorticoids were studied at least 24 h after their last dose. Disease activity was measured using the SLEDAI score (37) (mean±SD = 6.4±5.7). 15 patients were on prednisone, 13 on hydroxychloroquine, and 4 were on cytotoxic medications (1 on cyclophosphamide, 1 on methotrexate, and 2 were receiving azathioprine). An additional sample of 12 patients with other systemic autoimmune rheumatic diseases (disease-control group) was also studied. Of those patients, nine had rheumatoid arthritis, one had juvenile chronic arthritis, one had systemic sclerosis, and one had an undifferentiated connective tissue disease. Of these, 10 were women and 2 were men. The age range was similar to that of the SLE patient group (mean±SD = 43±14.5). The protocol was approved by the Health Use Committee at Walter Reed Army Medical Center or the Bowman Gray School of Medicine, and informed consent was obtained from all patients. 17 healthy volunteers were included in the control group.

Cells. Heparinized peripheral venous blood was obtained from study subjects. Leukopheresis samples were obtained from several healthy control individuals as well as certain SLE patients. PBMC were obtained by standard Ficoll-Hypaque gradient centrifugation. In most instances, this cell population was enriched in B cells by rosetting once or twice with sheep red blood cells, as described (38). Monocytes were depleted by adherence to plastic (39). The cell population was restaged overnight in a concentration of 1×10⁶ cells/ml in RPMI-1640 containing 10% FCS.

Reagents and mAbs. The F(ab')₂ fragment of an affinity-purified goat anti-human μ heavy chain Ab (Jackson ImmunoResearch Laboratories Inc., Avondale, PA), and two murine anti-human IgD monoclonal antibodies, 1 (CBDA-4E5-4C7 and 8IAG.2, both were generous gifts of Dr. Fred Finkelman) were used for the stimulation of lymphocytes. The fluorochrome-conjugated mAbs used were: anti-CD3 (IgG1)-FITC (Coulter, Hialeah, FL), anti-CD16 (Leu-11c)-phycoerythrin (PE) (a murine IgG1 mAb) and anti-CD14 (Leu-M3)-PE, anti-CD5 (IgG1)-FITC (Coulter, Hialeah, FL), anti-CD16 (Leu-11c)-phycoerythrin (PE) (a murine IgG1 mAb) (Becton-Dickinson Immunocytometry Systems, San Jose, CA), and the antiphosphotyrosine horseradish peroxidase (HRPO)-conjugated mAb (4G10) was purchased from Upstate Biotechnology Inc. (Lake Placid, NY). The dye Indo-1 acetoxy methylester (Molecular Probes, Eugene, OR) was dissolved in DMSO and stored at −70°C until use. Ficoll (Lymphoprep; Nycomed Pharma AS, Oslo, Norway), BSA, EGA, DTSA, DMSO, lithium chloride, calcium chloride, sodium formate, formic acid, disodium tetraborate, and ammonium formate were purchased from Sigma Chemical Co. (St. Louis, MO). Chloroform was purchased from J.T. Baker Chemical Company (Phillipsburg, NJ), methanol was purchased from Mallinckrodt (Paris, KY), and RPMI-1640, FCS, glutamine, streptomycin, penicillin, HBSS and Hepes were purchased from Life Technologies Laboratories Inc., Avondale, PA), and two murine anti–human IgD monoclonal antibodies, 1 (CBDA-4E5-4C7 and 8IAG.2, both were generous gifts of Dr. Fred Finkelman) were used for the stimulation of lymphocytes. The fluorochrome-conjugated mAbs used were: anti-CD3 (IgG1)-FITC (Coulter, Hialeah, FL), anti-CD16 (Leu-11c)-phycoerythrin (PE) (a murine IgG1 mAb) and anti-CD14 (Leu-M3)-PE, anti-CD5 (IgG1)-FITC (Coulter, Hialeah, FL), anti-CD16 (Leu-11c)-phycoerythrin (PE) (a murine IgG1 mAb) (Becton-Dickinson Immunocytometry Systems, San Jose, CA), and the antiphosphotyrosine horseradish peroxidase (HRPO)-conjugated mAb (4G10) was purchased from Upstate Biotechnology Inc. (Lake Placid, NY). The dye Indo-1 acetoxy methylester (Molecular Probes, Eugene, OR) was dissolved in DMSO and stored at −70°C until use. Ficoll (Lymphoprep; Nycomed Pharma AS, Oslo, Norway), BSA, EGA, DTSA, DMSO, lithium chloride, calcium chloride, sodium formate, formic acid, disodium tetraborate, and ammonium formate were purchased from Sigma Chemical Co. (St. Louis, MO). Chloroform was purchased from J.T. Baker Chemical Company (Phillipsburg, NJ), methanol was purchased from Mallinckrodt (Paris, KY), and RPMI-1640, FCS, glutamine, streptomycin, penicillin, HBSS and Hepes were purchased from Life Technologies Laboratories Inc., Avondale, PA), and two murine anti–human IgD monoclonal antibodies, 1 (CBDA-4E5-4C7 and 8IAG.2, both were generous gifts of Dr. Fred Finkelman) were used for the stimulation of lymphocytes. The fluorochrome-conjugated mAbs used were: anti-CD3 (IgG1)-FITC (Coulter, Hialeah, FL), anti-CD16 (Leu-11c)-phycoerythrin (PE) (a murine IgG1 mAb) and anti-CD14 (Leu-M3)-PE, anti-CD5 (IgG1)-FITC (Coulter, Hialeah, FL), anti-CD16 (Leu-11c)-phycoerythrin (PE) (a murine IgG1 mAb) (Becton-Dickinson Immunocytometry Systems, San Jose, CA), and the antiphosphotyrosine horseradish peroxidase (HRPO)-conjugated mAb (4G10) was purchased from Upstate Biotechnology Inc. (Lake Placid, NY). The dye Indo-1 acetoxy methylester (Molecular Probes, Eugene, OR) was dissolved in DMSO and stored at −70°C until use. Ficoll (Lymphoprep; Nycomed Pharma AS, Oslo, Norway), BSA, EGA, DTSA, DMSO, lithium chloride, calcium chloride, sodium formate, formic acid, disodium tetraborate, and ammonium formate were purchased from Sigma Chemical Co. (St. Louis, MO). Chloroform was purchased from J.T. Baker Chemical Company (Phillipsburg, NJ), methanol was purchased from Mallinckrodt (Paris, KY), and RPMI-1640, FCS, glutamine, streptomycin, penicillin, HBSS and Hepes were purchased from Life Technologies Laboratories Inc., Avondale, PA). The inositol phosphates (InsP) was diluted first with 2.3 ml of water and then with distilled water. The inositol phosphates (InsP) was diluted first with 2.3 ml of water and then with distilled water. The two-tailed unpaired Student’s t test was used to analyze the data. The mean±SEM were used for data expression. Values of P ≤ 0.05 were considered as significant.
systemic autoimmune rheumatic diseases.

than B cells from normal individuals and patients with other
diseases, and 17 healthy individuals. There were no significant
SLE patients, 14 patients with other autoimmune rheumatic
patients (7.27
were compared (A)

the fluorescence ratio (381/525 nm).

Results

SLE B cells display higher BCR-mediated \([Ca^{2+}]\), responses
than B cells from normal individuals and patients with other
systemic autoimmune rheumatic diseases. Five million PBMC
enriched in B cells were loaded with the calcium-binding dye
Indo-1 AM and stained with anti–CD3-FITC, anti–CD14-PE,
and anti–CD16-PE to gate out T cells, monocytes, and natural
killer cells, respectively. This negative selection enabled us to
measure changes in the levels of \([Ca^{2+}]\), in fresh, unmanipu-
lated B cells which were the only unstained cells in the lym-
phocyte subpopulation. Stimulation of cells was performed
with an F(ab')2 fragment of a goat anti–human \(\mu\) heavy chain Ab (A), the
\(\delta\)IAG.2 murine anti–human IgD mAb (B), and the CBDA-4E5-4C7
murine anti–human IgD mAb (C), produced maximal peaks of
\([Ca^{2+}]\), at concentrations of 40 \(\mu\)g/ml each. \([Ca^{2+}]\), was measured as the
fluorescence ratio (381/525 nm).

Figure 1. Dose–response curves of anti–sIg-induced increases in
\([Ca^{2+}]\). Three anti-sIg Abs were used in increasing concentrations to
stimulate B cell–enriched PBMC from healthy individuals. The
F(ab')2 fragment of a goat anti–human \(\mu\) heavy chain Ab (A), the
\(\delta\)IAG.2 murine anti–human IgD mAb (B), and the CBDA-4E5-4C7
murine anti–human IgD mAb (C), produced maximal peaks of
\([Ca^{2+}]\), at concentrations of 40 \(\mu\)g/ml each. \([Ca^{2+}]\), was measured as the
fluorescence ratio (381/525 nm).

Figure 2. Representative anti–sIg-induced \([Ca^{2+}]\), responses in lupus
patients and normal individuals. Five million PBMC enriched in B
cells were loaded with the calcium-binding dye Indo-1 AM and fluo-
rochrome-conjugated mAbs against non–B cell surface markers. Neg-
atively selected B cells were stimulated with anti-BCR Abs (40 \(\mu\)g/ml
each) after 60 s of resting (arrow), and the response was recorded for
a total of 10 min. The \([Ca^{2+}]\), is proportional to the recorded mean
fluorescence ratio (381/525 nm). In all three graphs, the highest curve
(---) represents the response of lupus B cells, and the lowest (solid
line) represents the response of B cells when medium only (instead of
Ab) was added (no response). The middle curve (...) in all three
graphs shows the response of normal B cells. Lupus B cells display
higher and more prolonged responses. Representative experiments
with the use of: (A) anti-sIgM; (B) CBDA-4E5-4C7 anti-IgD mAb;
and (C) \(\delta\)IAG.2 anti-IgD mAb.

Although the peak \([Ca^{2+}]\), recordings were similar between
the normal individuals and the disease controls (10.41±0.53 vs
10.65±0.59, \(P<0.78\)), the peak \([Ca^{2+}]\), responses were signifi-
cantly higher (14.60±0.90) in the SLE patient group. The peak
response of lupus B cells was higher compared to the group of
healthy volunteers (\(P<0.002\)) and was also significantly
higher in comparison with the group of patients with other auto-
immune diseases (\(P<0.005\)) (Fig. 3).

Any slg isotype can participate in the formation of the
BCR complex and the initiation of the B-cell signaling process,
but the vast majority of B-cells carry BCRs comprising slgM
and slgD (44). To examine whether the abnormal \([Ca^{2+}]\), re-
response was restricted to slgM-BCR, we used two different
anti-slgD murine mAbs to stimulate human B cells and re-
corded the changes in the levels of \([Ca^{2+}]\). The two murine
mAbs, CBDA-4E5-4C7 and \(\delta\)IAG.2, were used at concentra-
**Figure 3.** Anti-sIgM induced \([\text{Ca}^{2+}]_i\), responses in control, disease control, and SLE B cells. PBMC enriched in B cells were stimulated with 40 \(\mu\)g/ml of the F(ab')\(_2\) fragment of a goat-anti-human \(\mu\) Ab. The base line and the peak responses of intracellular free \(\text{Ca}^{2+}\) were recorded. While the base line values obtained were similar between the three groups, the peak \([\text{Ca}^{2+}]_i\), responses were significantly higher in the lupus patients group compared to the control (\(P < 0.002\)), as well as to the disease control group (\(P < 0.005\)). Bars represent the mean±SEM.

**Figure 4.** Anti-sIgD initiated \([\text{Ca}^{2+}]_i\), responses using the CBDA-4E5-4C7 murine anti-human mAb. Base line values and peak \([\text{Ca}^{2+}]_i\) responses were recorded for B cells obtained from normal individuals and from lupus patients. Stimulation was performed with 40 \(\mu\)g/ml of the Ab. Significantly higher peak free intracellular \(\text{Ca}^{2+}\) responses were observed for the SLE patients group (\(P < 0.01\)). Bars represent the mean±SEM.

**Figure 5.** Anti-sIgD initiated \([\text{Ca}^{2+}]_i\), responses using the \(\delta\)IAG.2 murine anti-human mAb. Equal numbers of SLE and healthy individuals' B cells were stimulated with 40 \(\mu\)g/ml of this mAb. Lupus B cells responded higher than the controls but the difference did not reach statistical significance (\(P < 0.07\)). Bars represent the mean±SEM.

**Figure 6.** Anti-sIgM-induced \(\text{InoP}_3\) production. The release of intracellularly stored \(\text{Ca}^{2+}\) from the endoplasmic reticulum to the cytoplasm occurs upon binding of the second messenger \(\text{InoP}_3\) to its receptor (\(\text{InoP}_3\)R). To investigate whether the increased
Table I. Contribution of Intracellularly Stored Calcium to the [Ca\(^{2+}\)] Response as Measured by EGTA Treatment of Normal and Lupus B Cells*

<table>
<thead>
<tr>
<th>EGTA treatment</th>
<th>SLE (n)</th>
<th>Control (n)</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>1.97±0.11 (5)</td>
<td>1.27±0.05 (3)</td>
<td>0.004</td>
</tr>
<tr>
<td>Yes</td>
<td>1.59±0.12 (5)</td>
<td>1.13±0.04 (3)</td>
<td>0.031</td>
</tr>
</tbody>
</table>

*Values obtained before and after the addition of 5 mM EGTA refer to the same SLE patients or normal individuals. The ratio of the peak over the base fluorescence values for [Ca\(^{2+}\)] was estimated, and the mean±SEM are represented here for each group. \(^{\dagger}\)Values of \(P\) < 0.05 were considered as statistically significant.

[Ca\(^{2+}\)] response in lupus B cells after crosslinking of the sIgM is due to increased InsP\(_3\) production, we incubated PBMC enriched in B cells with tritiated myoinositol, stimulated them with 20 \(\mu\)g of the F(\(ab'\))\(_2\) fragment of a goat-anti–human \(\mu\) Ab, and measured the inositol phosphate metabolites using anion-exchange chromatography at three time-points (0, 5, and 10 min after the addition of anti-sIgM Ab). Fig. 6 shows one representative experiment of four. The anti-sIgM-induced levels of inositol phosphate metabolites were always slightly higher than the levels that were observed in normal cells, but the difference did not reach statistical significance. These experiments show that the observed increased BCR-mediated [Ca\(^{2+}\)] responses in lupus B cells do not appear to be due to increased BCR-induced InsP\(_3\) production.

The anti-sIgM-induced phosphorylation of protein tyrosine residues is increased in lupus B cells. Perhaps the earliest event after the BCR ligation is the activation of a cascade of protein tyrosine kinases, which phosphorylate various proteins on tyrosine residues. Several quite important cellular functions are executed and regulated by the action of these kinases, the calcium response being one of them. As has been shown in several cell types including B cells, modulations in the action of the "pre-Ca\(^{2+}\)" kinases may lead to altered calcium responses. Over or underexpression of members of this pathway in immune cells results in increased or decreased activity of the kinases and may modify the amount of Ca\(^{2+}\) mobilization (45–48). Since we observed increased BCR-initiated [Ca\(^{2+}\)] values in lupus B cells we conducted experiments to determine whether this phenomenon was correlated with altered BCR-mediated overall "pre-Ca\(^{2+}\)" protein tyrosine kinase (PTK) activity.

An equal number of PBMC enriched in B cells was stimulated with 20 \(\mu\)g of the F(\(ab'\))\(_2\) fragment of a goat-anti–human \(\mu\) Ab for 60 s, a time that has been known to be required for maximal anti-sIgM-induced PTK activity (49). After lysing the cells, an equal amount of protein was electrophoretically separated on gels, transferred on membranes and blotted with an anti-phosphotyrosine-HRPO-conjugated mAb. Results show (Fig. 7), that in two out of three SLE patients examined, the overall degree of tyrosine phosphorylation was obviously increased. Although we did not notice the appearance of new
bands the intensity of at least four of them, located between the 64- and the 36-kD mol wt standards, was obviously enhanced. Moreover, the intensity of these bands (determined densitometrically) was directly proportional to the magnitude of the Ca^{2+} response for each individual SLE patient studied. The activity/availability therefore of the PTKs assessed by the densitometric analysis corresponded to the initially recorded higher peak [Ca^{2+}] response in lupus B cells.

[Ca^{2+}], responses in SLE B cells do not correlate with disease activity and treatment status. At the time of the study, an SLEDAI score was determined for each patient and treatment, if any, consisting of prednisone, hydroxychloroquine, and cytotoxic drugs (azathioprine, cyclophosphamide, methotrexate) was also recorded. Patients were classified as having active disease when the SLEDAI score was four or higher. Table II shows that there were no significant differences among patients with active or inactive disease at the time of the study. Moreover, treatment status did not affect the recorded responses. The lupus group had significantly higher peak/baseline ratios when compared with the control group (P = 0.001) and to the disease–control group (P = 0.01). The lack of any correlation between Ca^{2+} responses and the activity of the disease suggests that the cell signaling abnormalities reported herein may be of pathogenetic importance.

### Discussion

We conducted the present study to investigate the possible aberrations in the early events of the signal transduction pathway in lupus B cells. Our purpose was to test the hypothesis that B cells in SLE are not innocent bystanders of an altered T cell activity but exhibit inherent biochemical defects. We used anti-sIgM and anti-sIgD Abs to stimulate fresh, unmanipulated B cells from lupus, disease controls, and normal individuals, and evaluated the [Ca^{2+}] response, the tyrosine phosphorylation pattern and the inositol phosphate metabolite production. We found that lupus, but not disease control, B cells exhibit significantly higher responses regardless of the crosslinking anti-sIg Ab that did not correlate with disease activity or treatment status.

Our findings clearly demonstrated that the anti-sIgM-induced peak [Ca^{2+}], responses were significantly higher in lupus B cells compared with responses of B cells from the normal group, although their resting [Ca^{2+}], were similar. Moreover, the peak [Ca^{2+}], values recorded for lupus B cells were also significantly higher than those observed for B cells obtained from patients with other systemic autoimmune rheumatic diseases. This latter group of patients had baseline as well as peak [Ca^{2+}], responses similar to the normal group. Our results suggest the existence of an SLE-specific abnormality in the signaling events in lupus B cells.

The vast majority of B cells are sIgM and sIgD positive. No differences in the expression of these two surface immunoglobulins were found between lupus and normal B cells (data not shown). To test whether or not our results were sIgM specific, we evaluated the anti-sIgD-mediated Ca^{2+} responses using two different murine anti-IgD mAbs. The anti-sIgD-induced responses were again significantly enhanced for one of the two mAbs used, while the other produced higher but not statistically significant elevations. The anti-sIgD recorded Ca^{2+} fluxes were shorter in duration than the responses to anti-sIgM, in accordance with previously described data (50). These findings indicate that SLE B cells exhibit a disease-specific abnormality in the BCR-mediated [Ca^{2+}], responses.

The Ca^{2+} response to ligation of the BCR results from the release of stored calcium from the internal stores to the cytoplasm initially followed by influx of the ion from the extracellular space. By adding the chelating agent EDTA to the medium immediately before the recording, we were able to study the release of the ion from the endoplasmic reticulum. These experiments yielded an augmented [Ca^{2+}], response in lupus B cells, suggesting that increased release of stored Ca^{2+} contributes to the initially recorded higher peak [Ca^{2+}] responses in B cells from patients with SLE.

The BCR complex is a hetero-oligomer, consisting of the surface immunoglobulin molecule and the Ig-α/β heterodimer(s) (51, 52). The latter two molecules are responsible for the signal-transducing properties of the antigen receptor (43). The signaling motif ITAM (Ig [superfamily] tyrosine-based activation motif) is present in the cytoplasmic tails of both Ig-α and Ig-β (54). ITAM has been shown to be sufficient and necessary to carry out signaling functions, including PTK activation, protein tyrosine phosphorylation, and Ca^{2+} mobilization (22). PTKs involved include the src-family members p55^src, p59^src, and p53/56^fyn and the cytoplasmic PTK p72^src (55–57). After sIg ligation p72^src becomes autophosphorylated first (58, 59), which leads to binding of the src-family kinases through their SH-2 domains, derepressing tyrosyl kinase activation (60). This, in turn, leads to tyrosyl phosphorylation of Ig-α and Ig-β ITAMs (61), with resultant activation, reorientation and recruitment of additional src-family kinase molecules (62). The activated src-family kinases regulate several cascades including the activation of PLCγ2, of mitogen-activated protein kinase (MAPK), of GTPase-activating protein (GAP), of the p21ras pathway, and of phosphoinositide 3-kinase (PI 3-K) (63–65).

Ligation of either sIgM or sIgD results in the activation of the same PTKs, which in turn phosphorylate the same substrates (66–68) and consequently lead to the Ca^{2+} mobilization response (69). Both “precalcium” segments are qualitatively, but not quantitatively, identical, since their regulatory mechanisms might differ (49). The “postcalcium” events might be quite dissimilar as well (70, 71).

### Table II. Correlation between Disease Activity, Treatment Regimes, and [Ca^{2+}], Responses in Lupus B Cells

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Peak/baseline [Ca^{2+}], ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Present (n)</td>
</tr>
<tr>
<td>SLEDAI score ≥ 4</td>
<td>2.05±0.06 (15)</td>
</tr>
<tr>
<td>Prednisone</td>
<td>2.04±0.16 (15)</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>1.93±0.15 (13)</td>
</tr>
<tr>
<td>Cytotoxicities</td>
<td>2.51±0.46 (4)</td>
</tr>
<tr>
<td>SLE</td>
<td>2.04±0.13 (21)</td>
</tr>
</tbody>
</table>

* Disease activity and form of treatment were determined at the time of the study for each patient. The ratio of the peak over the base fluorescence values for [Ca^{2+}], was estimated, and the mean±SEM are represented here for each subgroup. §value for the whole SLE patient group; †value for the whole group of healthy individuals; ‡statistically significant (P < 0.05).
Therefore, BCR ligation leads to immediate activation of several PTKs and phosphorylation of substrates on tyrosine residues. To investigate the relative amount of early tyrosine phosphorylation in B cells from SLE patients, we immunoblotted lysates from SLE and control B cells activated with anti-slgM, with an antiphosphotyrosine mAb. There were no differences in the amount of tyrosine phosphorylated substrates between lupus and normal B cells in the resting state. After 60 s of stimulation with the same F(ab\(^{-}\))\_2 anti-\_B fragment we observed markedly enhanced tyrosine phosphorylation of several protein bands from lupus samples, indicating increased PTK activation in lupus B cells compared with normal controls. Even though the cell populations used did not consist of pure B cells (> 90% B cells determined flow cytometrically), the stimulus that we used is B cell specific because only B cells bear slgM. Thus, any resultant increase in tyrosine phosphorylation of substrates, cannot be attributed to any other cell subpopulation.

Interestingly, the amount of inositol phosphate metabolites InsP\(_2\), InsP\(_3\), and, more importantly, of InsP\(_3\) produced after slgM stimulation, were only slightly, but not statistically significantly, higher in lupus than in normal cells. One explanation for this discrepancy between increased Ca\(^{2+}\) responses and normal InsP\(_3\) production may be an increased density of InsP\(_3\)/Ca\(^{2+}\) stores in the lupus cells, as has been described in some cell types (72, 73). Alternatively, increased InsP\(_3\)/Ca\(^{2+}\) binding resulting in enhanced release of calcium may be present. The sensitivity of the InsP\(_3\)/Ca\(^{2+}\)R is regulated by InsP\(_3\) itself, by Ca\(^{2+}\) and by PTK-mediated phosphorylation (74). Interestingly, antigen receptor-mediated and Fyn-dependent phosphorylation of the InsP\(_3\)/Ca\(^{2+}\)R caused higher responses in T cells and also increased the inhibitory threshold of rising [Ca\(^{2+}\)]\_i on the receptor. Increased availability or activity, therefore, of certain PTKs influences the sensitivity of the calcium channels and promotes increased responses upon antigen receptor stimulation. To date, similar studies have not been performed on normal or lupus B cells. Finally, an InsP\(_3\)-independent Ca\(^{2+}\) mobilizing mechanism may be operative in SLE B cells. Evidence that such a mechanism might exist is provided from experiments with B cells and other cell types (45–47). This might implicate abnormal expression of certain protein tyrosine kinases in SLE B cells. Such evidence has been provided by the recent finding of overexpression of the p59\(^{fyn}\) in T cells from the lpr/lpr murine model of SLE and from transfected cells overexpressing p59\(^{fyn}\) (47, 48). At present, no data exist for B cells.

Work from this laboratory has recently shown that a similar abnormality in the antigen receptor-mediated Ca\(^{2+}\) response is associated with normal InsP\(_3\) production in lupus T cells as well (41). The tyrosine phosphorylation pattern was not addressed. It may be, therefore, appropriate to assume that lupus T and B cells display similar cell signaling-associated biochemical abnormalities. Why do lupus B and T cells respond in an altered manner to stimuli that closely mimic physiologic stimuli? The recent description by Kammer et al. (42) that lupus T cells have abnormally low levels of the cAMP-sensitive K\(^+\) channel may offer some explanation. The intracellular levels of cAMP and the activity of this enzyme can influence the Ca\(^{2+}\) response after antigen receptor ligation in T cells (75–77). Since increased cAMP and PKA activity can down regulate the calcium response, our observation of heightened [Ca\(^{2+}\)]\_i values might be explained by a diminished function of the cAMP/PKA system. Recently, a cAMP-sensitive K\(^+\) channel was also described on the plasma membrane operating in activated cells only. An increase in intracellular cAMP acting on this channel influences adversely the magnitude of the free Ca\(^{2+}\) response (78). Increased [Ca\(^{2+}\)]\_i responses as the ones we describe could be then attributed to decreased intracellular cAMP.

Provided that the same PTK enzymatic defect exists in SLE B cells, we hypothesize that the defective inhibitory cAMP/PKA-I pathway might contribute to the augmented [Ca\(^{2+}\)]\_i responses of the lupus immune cells. Evidence that further supports this hypothesis was provided from the study of a single patient, (included in our SLE patients group), who had unusually normal cAMP-dependent PKA-I activity in her T cells. As could be predicted from the above hypothesis, her BCR-induced [Ca\(^{2+}\)]\_i response was normal. More work is necessary though, (a) to establish that this enzymatic defect also characterizes lupus B cells, (b) to examine whether other patients as the one mentioned above respond in the same way and (c) to determine the availability and/or activity of each one of the early protein kinase systems.

The function of intracellular Ca\(^{2+}\) underlines the physiologic importance of our findings. Numerous intracellular enzymes and a spectrum of diverse and even quite opposite cellular functions are Ca\(^{2+}\) regulated (22, 27, 79–81). Indeed, abnormalities of some of these functions have been described in the human and the murine lupus (82–85). In this study we have demonstrated that lupus B cells exhibit abnormal early signal transduction events. Because these abnormalities were not related to disease activity and because they were limited to lupus B cells, we conclude that they may be due to intrinsic defect(s) of the B cell, which may contribute to the pathogenesis of the disease.

Acknowledgments

We are indebted to Dr. Fred Finkelman for valuable comments at the beginning of the study and his generous supply of anti-IgD mAbs. The expert help of Mr. Lloyd Billups with the flow cytometer is appreciated.

Dr. Liossis was supported in part by a scholarship from the Hellenic Society of Rheumatology. This study was supported by work unit 9297 from the Department of Clinical Investigation, Walter Reed Army Medical Center. The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of the Army or the Department of Defense.

References


